CRD-740
/ Cardurion
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
October 31, 2025
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.
(PubMed, JACC Heart Fail)
- P2 | "In this initial phase 2 trial, PDE9 inhibition with CRD-740 was well tolerated and resulted in elevations of plasma and urinary cGMP on top of standard care, including sacubitril/valsartan, supporting the potential of PDE9 inhibition to enhance the beneficial effects of the natriuretic peptide receptor-cGMP pathway incremental to existing heart failure treatments. (Effectiveness of CRD-740 in Heart Failure [CARDINAL-HF]; NCT05409183)."
Clinical • Journal • P2 data • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension
May 14, 2024
A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure
(ESC 2024)
- No abstract available
Clinical • P2 data • PK/PD data • Cardiovascular • Congestive Heart Failure • Heart Failure
April 05, 2024
A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure
(HEART FAILURE 2024)
- No abstract available
Clinical • Late-breaking abstract • P2 data • PK/PD data • Cardiovascular • Congestive Heart Failure • Heart Failure
November 07, 2023
CARDINAL-HF: Effectiveness of CRD-740 in Heart Failure
(clinicaltrials.gov)
- P2 | N=60 | Terminated | Sponsor: Cardurion Pharmaceuticals, Inc. | N=660 ➔ 60 | Trial completion date: Jan 2024 ➔ Jul 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: Dec 2023 ➔ May 2023; Part A of the study was successfully concluded. Part B of the study was discontinued in favor of redesigned new studies.
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Cardiovascular • Congestive Heart Failure • Heart Failure
May 09, 2023
CARDINAL-HF: Effectiveness of CRD-740 in Heart Failure
(clinicaltrials.gov)
- P2 | N=660 | Active, not recruiting | Sponsor: Cardurion Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Cardiovascular • Congestive Heart Failure • Heart Failure
February 06, 2023
Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740
(clinicaltrials.gov)
- P1 | N=20 | Completed | Sponsor: Cardurion Pharmaceuticals, Inc. | Recruiting ➔ Completed
Trial completion • Cardiovascular • Heart Failure
June 29, 2022
Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: Cardurion Pharmaceuticals, Inc.
New P1 trial • Cardiovascular • Heart Failure
June 08, 2022
CARDINAL-HF: Effectiveness of CRD-740 in Heart Failure
(clinicaltrials.gov)
- P2 | N=660 | Recruiting | Sponsor: Cardurion Pharmaceuticals, Inc.
New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure
1 to 8
Of
8
Go to page
1